Paratek Pharmaceuticals
(NASDAQ) PRTK
Paratek Pharmaceuticals Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$167.74M
Net Income (TTM)
$67.12M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
PRTK News
PRTK: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Paratek Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
268
CEO
Evan Loh, MD
Website
www.paratekpharma.comHeadquarters
Boston, MA 02116, US
PRTK Financials
Key Financial Metrics (TTM)
Gross Margin
85%
Operating Margin
-31%
Net Income Margin
-42%
Return on Equity
43%
Return on Capital
-34%
Return on Assets
-37%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$127.73M
Operating Income
$46.21M
EBITDA
$44.90M
Operating Cash Flow
$66.14M
Capital Expenditure
$36.00K
Free Cash Flow
$66.18M
Cash & ST Invst.
$34.25M
Total Debt
$258.41M
Paratek Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$38.06M
+38.1%
Gross Profit
$33.69M
+48.6%
Gross Margin
88.52%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
268
N/A
Net Income
$14.55M
+34.1%
EBITDA
$9.17M
+29.2%
Quarterly Fundamentals
Net Cash
$217.07M
-15.1%
Accounts Receivable
$42.51M
+33.6%
Inventory
$11.41M
-12.8%
Long Term Debt
$95.71M
-62.9%
Short Term Debt
$164.04M
N/A
Return on Assets
-36.84%
N/A
Return on Invested Capital
-34.19%
N/A
Free Cash Flow
$1.78M
+87.8%
Operating Cash Flow
$1.78M
+87.8%